Business Context and Reporting Period
Clearmind Medicine Inc., a foreign private issuer, filed Form 6-K for the month of May 2026, dated May 18, 2026. The filing reports on a specific financing transaction rather than providing comprehensive periodic financial results.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or total debt levels. The only specific financial data disclosed relates to a new debt issuance:
- Promissory Notes Issued: $600,000 aggregate principal amount.
- Purchase Price: $540,000 (90% of principal).
- Discount: 10% discount on the principal amount.
- Expected Closing Date: On or about May 19, 2026.
Material Changes
The material change reported is the execution of an agreement on May 18, 2026, with "CLA Investors" to issue convertible promissory notes. This transaction operates under an amended securities purchase agreement (SPA) originally dated September 17, 2025, which allows for the issuance of up to $10,000,000 in aggregate principal notes. This specific tranche represents a $600,000 drawdown against that facility.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies beyond the terms of the note issuance. The transaction is expected to close shortly after the filing date.
Investor Verification Checklist
- Verify the closing of the $540,000 cash transaction on or about May 19, 2026.
- Review the full terms of the convertible promissory notes, including conversion rates, maturity dates, and interest rates, which are not detailed in this summary.
- Confirm the remaining availability under the $10,000,000 aggregate principal facility established in September 2025.
- Check for subsequent filings regarding the dilution impact of the convertible notes upon conversion.